# A Prospective Study of Constructing Immune Repertoire to Monitor the Therapeutic Effect in NSCLC Patients

> **NCT03373955** · — · UNKNOWN · sponsor: **Sichuan University** · enrollment: 60 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** pembrolizumab

## Key facts

- **NCT ID:** NCT03373955
- **Lead sponsor:** Sichuan University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-11-23
- **Primary completion:** 2021-07-31
- **Final completion:** 2021-12-31
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2021-03-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03373955

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03373955, "A Prospective Study of Constructing Immune Repertoire to Monitor the Therapeutic Effect in NSCLC Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03373955. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*